Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 30 clinical trials
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Pembrolizumab in the Treatment of Patients With Relapsed and Refractory Lymphoma

This is a two-phase, open-label Phase Ib clinical trial to evaluate the safety and efficacy of TQB2618 injection combined with piamprilumab in patients with relapsed and refractory lymphoma

  • 0 views
  • 17 Jun, 2022
  • 1 location
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, …

  • 0 views
  • 04 Oct, 2022
  • 4 locations
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

measurable disease
stem cell transplantation
  • 0 views
  • 04 Oct, 2022
  • 48 locations
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists

leukemia
follicular lymphoma
waldenstrom's macroglobulinemia
marginal zone lymphoma
chronic lymphocytic leukemia
  • 0 views
  • 19 Sep, 2022
  • 21 locations
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma

An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas

lymphoma
  • 0 views
  • 20 Sep, 2022
  • 26 locations
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas.

This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and have at least one measurable lesion according to …

rituximab
monoclonal antibodies
measurable disease
lymphoma
  • 0 views
  • 22 Sep, 2022
  • 21 locations
Molecular Analysis for Therapy Choice (MATCH)

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic …

afatinib
major surgery
screening method
gnrh
luteinizing hormone
  • 6585 views
  • 14 Sep, 2022
  • 911 locations
CMP-001 for Relapsed and Refractory Lymphoma

patients with relapsed and refractory lymphomas.

therapeutic agents
antibody therapy
refractory lymphoma
hodgkin's disease
measurable disease
  • 1 views
  • 02 May, 2022
  • 1 location
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat to …

bone marrow procedure
neutrophil count
hodgkin's disease
measurable disease
lymphoma
  • 26 views
  • 04 Oct, 2022
  • 9 locations
  • 2 views
  • 21 Mar, 2022